Skip to main content
Clinical Trials/NCT02784730
NCT02784730
Withdrawn
Phase 3

A Randomized, Multicentre, Comparative Phase III Study of Catheter-related Complications of an Iterative PICC Placement vs a Long-term PAC in Patients With Breast Cancer

Centre Leon Berard1 site in 1 countryJanuary 10, 2018
ConditionsBreast Cancer

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Centre Leon Berard
Locations
1
Primary Endpoint
Compare complication rate for iterative placement (PICC) versus long term placement (PAC).
Status
Withdrawn
Last Updated
8 years ago

Overview

Brief Summary

Peripherally Inserted Central Catheter (PICC) and port-a-cath (PAC) are the most commonly medical devices used for the administration of chemotherapy.

Placement of these devices via central venous access is sometimes responsible for complications.

The incidence of these complications is correlated with the device holding time.

A strategy of iterative PICC placement could significantly reduce these complications.

Registry
clinicaltrials.gov
Start Date
January 10, 2018
End Date
January 10, 2018
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women older than 18 years old;
  • Breast cancer diagnosis histologically proven , for any histological subtypes;
  • 4 or 6 indication of neoadjuvant or adjuvant chemotherapy; according to hormonal status and HER2 of the tumors, the patient may be treated concomitantly with hormone therapy and / or trastuzumab; Nota Bene: treatment protocol adopted will imperatively be administered in 3-week cycles.
  • Central venous access indication;
  • Ability to understand and willingness to comply with the study monitoring;
  • Affiliated to the French social security system;
  • Informed Consent dated and signed, indicating that the patient has been informed of all pertinent aspects of the study before inclusion.

Exclusion Criteria

  • Any contraindication for placement of a central venous catheter ( hemostasis disorders , active infection treated with antibiotics , ...);
  • Patient who can't stop anti -vitamin K treatment ( AVK ) ( a relay by Heparin Low Molecular Weight (LMWH) is possible);
  • History of central access, regardless of the indication;
  • Any active disease other than cancer pathology , requiring repeated administration of intravenous therapy ;
  • Patient deprived of liberty;
  • Not monitoring for social, geographical, psychological or family reason.

Outcomes

Primary Outcomes

Compare complication rate for iterative placement (PICC) versus long term placement (PAC).

Time Frame: 6 months after randomization

Complication rate will be defined by the proportion of patients with at least one of the following complications from the date of randomization to the end of the study: pneumothorax , hemothorax ,veinous thrombosis, migration or expulsion of the device, fissure or rupture of the catheter, catheter obstruction, extravasation.

Secondary Outcomes

  • Success rate for each strategy(6 months after randomization)
  • Description of failure causes for each strategy(6 months after randomization)
  • Quality of Life in both arms(At Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1)
  • Level of pain for each strategy(At Cycle 1 Day 1, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1)

Study Sites (1)

Loading locations...

Similar Trials